Allakos(us:ALLK)

0.3150

-1.56%

Updated on 2025-04-04

Open:0.3200
Close:0.3150
High:0.3228
Low:0.3141
Prev Close:0.3200
Volume:2.14M
Turnover:680554.81
Turnover Ratio:2.37%
Shares:90.20M
MarketCap:28.41M
DateTotalTotal SharesTotal RatioNewIncreasedDecreased
2024-06-301237559729785.08%231761
2024-03-311197989602490.23%163152
2023-12-311317546320886.00%152368
2023-09-301427244721282.82%153965
2023-06-301557006321380.70%264169
2023-03-311476831287778.92%234855
2022-12-311456938248181.26%423842
2022-09-301306524160476.58%302654
dateorgNametotalratiochangeShareschangeRatio
2024-03-31Bvf Inc/Il1655241718.69%800000093.54%
2024-03-31Nea Management Company, Llc61472606.94%0
2024-03-31Deep Track Capital, Lp50000005.65%248926499.14%
2024-03-31Blackrock Inc.47207715.33%-395317-7.73%
2024-03-31Vanguard Group Inc37947294.29%53908716.56%
2024-03-31Redmile Group, Llc34510763.90%-219371-5.98%
2024-03-31Millennium Management Llc32534203.67%2291706238.29%
2024-03-31Citadel Advisors Llc30465833.44%-198339-6.11%
2024-03-31Vivo Capital, Llc29880003.37%0
2024-03-31Logos Global Management Lp29000003.28%0

About

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.
Address:825 Industrial Road,Suite 500

Market Movers